Media Articles Related to Bicalutamide
Cancer Experts Criticize Report on Rising Prostate Cancer Numbers
Source: MedicineNet Prostate Cancer Specialty [2016.07.22]
Title: Cancer Experts Criticize Report on Rising Prostate Cancer Numbers
Category: Health News
Created: 7/21/2016 12:00:00 AM
Last Editorial Review: 7/22/2016 12:00:00 AM
MRI Is 'Feasible' Prostate Cancer Screening Test
Source: Medscape Radiology Headlines [2016.07.19]
This is the first study of MRI as an initial screening test; the results are promising, say the investigators
Medscape Medical News
Number of Advanced Prostate Cancer Cases Soars: U.S. Study
Source: MedicineNet Prostate Cancer Specialty [2016.07.19]
Title: Number of Advanced Prostate Cancer Cases Soars: U.S. Study
Category: Health News
Created: 7/19/2016 12:00:00 AM
Last Editorial Review: 7/19/2016 12:00:00 AM
Prostate cancer: Unexpected results from international Phase III study
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.07.12]
A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any...
Prostate cancer and DNA mutation: New connections revealed
Source: Prostate / Prostate Cancer News From Medical News Today [2016.07.07]
A new relationship between mutations in specific DNA repair genes and metastatic prostate cancer is found. A new approach to treatment may be on the cards.
Published Studies Related to Bicalutamide
Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. [2010.12]
BACKGROUND: Bicalutamide is an oral nonsteroidal antiandrogenic drug used in the treatment of prostate cancer. A new generic 50-mg tablet formulation of bicalutamide has recently been developed. OBJECTIVE: This study evaluated the relative bioavailability and tolerability of the new generic formulation of bicalutamide 50-mg tablets (test) and the currently marketed formulation (reference) in healthy Korean male subjects. The study was conducted to meet Korean regulatory requirements for authorization to market the generic formulation... CONCLUSIONS: In this single-dose study in healthy Korean male subjects, the pharmacokinetic parameters of the new generic formulation of bicalutamide 50-mg tablets did not differ significantly from those of the reference formulation. The new generic formulation met Korean regulatory criteria for the assumption of bioequivalence to the currently marketed formulation. Both formulations were well tolerated. Korea Food and Drug Administration registration number: PSPD 3057. Copyright (c) 2010 Elsevier HS Journals, Inc. All rights reserved.
An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. [2010.02]
BACKGROUND: Bicalutamide monotherapy is a valuable option for prostate cancer (PCa) patients who wish to avoid the consequences of androgen deprivation; however, this treatment induces gynaecomastia and mastalgia in most patients. Tamoxifen is safe and effective in preventing breast events induced by bicalutamide monotherapy without affecting antitumor activity, but possible interference between bicalutamide and tamoxifen remains a matter of concern. To reduce the exposure to tamoxifen, we considered the putative advantages of weekly administration. OBJECTIVE: To compare the efficacy of two different schedules of tamoxifen in preventing breast events. Toxicity, prostate-specific antigen behaviour, and sexual-functioning scores were also evaluated... CONCLUSIONS: This study demonstrated that tamoxifen 20mg/wk is inferior to tamoxifen 20mg/d in preventing the incidence and severity of bicalutamide-induced breast events. The safety and efficacy of tamoxifen at the common daily dose of 20mg for the prophylaxis of bicalutamide-induced breast events were confirmed. Copyright 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. [2009.12]
BACKGROUND: Bicalutamide is an oral nonsteroidal antiandrogen drug used during hormone ablation therapy for prostate cancer. A new generic formulation of bicalutamide has been developed... Both formulations were generally well tolerated, with no clinically relevant safety concerns.
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. [2009.08.01]
BACKGROUND: A previously reported, double-blind, randomized, multicenter phase 3 trial in 205 patients with stage C/D prostate cancer compared combined androgen blockade (CAB) with luteinizing hormone-releasing hormone agonist (LHRH-A) plus bicalutamide 80 mg versus LHRH-A plus bicalutamide-matching placebo (LHRH-A monotherapy). The analysis at a median follow-up of 2.4 years indicated that CAB significantly (P<.001) prolonged the time to progression and the time to treatment failure. In the current report, survival data from a long-term follow-up (median, 5.2 years) were analyzed... CONCLUSIONS: CAB with bicalutamide 80 mg offered a significant overall survival benefit compared with LHRH-A monotherapy without reducing tolerability in patients with locally advanced or metastatic prostate cancer. Copyright (c) 2009 American Cancer Society.
Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. [2009.04]
BACKGROUND: Men with elevated prostate-specific antigen (PSA) and negative prostate biopsies are at risk for prostate cancer. The antiandrogen bicalutamide has a prolonged half-life, thus potentially allowing an intermittent administration to retain activity while reducing toxicity. We conducted a phase I-II trial of weekly bicalutamide in men with PSA >4 ng/mL and negative biopsies... CONCLUSIONS: A weekly administration of bicalutamide seems to be reasonably safe and shows an encouraging signal of activity on HG-PIN prevalence, supporting further studies of this schedule in men at high risk despite the negative primary end-point findings on Ki-67.
Clinical Trials Related to Bicalutamide
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy [Active, not recruiting]
The purpose of this study is to determine if a combination of neoadjuvant dutasteride and
bicalutamide has the same efficacy and less toxicity than standard treatment with an LHRH
agonist and bicalutamide for prostate cytoreduction prior to permanent implant
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer [Recruiting]
To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in
combination with daily bicalutamide and LH-RH agonists to men with non castrate metastatic
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer [Terminated]
The goal of this clinical trial is to learn if the study drug RAD001 in combination with
Bicalutamide can slow the growth of prostate cancer. The safety of RAD001 given together
with Bicalutamide will also be studied. RAD001 has been shown to kill prostate cancer
cells. In addition, several hundred kidney and heart transplant patients have been treated
with the same main ingredient as in RAD001 for many years.
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Active, not recruiting]
This randomized phase II trial is studying how well giving pazopanib with or without
bicalutamide works in treating patients with prostate cancer that did not respond to hormone
therapy. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of
prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of
androgens made by the body. Giving pazopanib hydrochloride together with bicalutamide may be
an effective treatment for prostate cancer.
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer [Active, not recruiting]
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy,
such as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying bicalutamide and everolimus to see how well they
work compared with bicalutamide in treating patients with recurrent or metastatic prostate
Reports of Suspected Bicalutamide Side Effects
Oedema Peripheral (7),
Cardiac Failure Congestive (6),
Dilatation Ventricular (5),
Prostate Cancer (5),
Vision Blurred (5),
Drug Interaction (4),
Interstitial Lung Disease (4), more >>